title: [Acute glaucine syndrome in the physician's practice: the clinical picture and potential danger].
abstract: The author describes a clinical symptom complex which appears in some patients as a central nervous system side-effect of conventional doses of glaucine, a non-narcotic antitussive preparation, used in outpatients; the symptom complex is described by the author as acute glaucine syndrome (AGS). Clinical manifestations of AGS are the following: 1) very prominent fatigue, which occurs acutely after taking a conventional dose of glaucine and making any kind of professional activity impossible at the moment; 2) very prominent sleepiness, which occurs acutely together with fatigue and is always combined with it; 3) unusual clear but somewhat estranged perception of the environment: the patient sees and understands everything and is oriented well enough, but cannot take a clear and adequate action, 4) full recovery of the impaired functions after the drug is discontinued; 5) AGS recurrence after the drug is taken again. The hallucination-like effect of glaucine, described earlier by the author of this article, which is manifested by bright and colorful visual images, may be considered a facultative AGS component. The author stresses a potential danger of AGS development in persons who control moving mechanisms or vehicles and adduces some clinical observations.
authors.forename: V I
authors.initials: VI
authors.lastname: Rovinskiĭ
mesh_terms: D000208:Acute Disease; D000328:Adult; D000996:Antitussive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001060:Aporphines / Q000009:adverse effects* / Q000627:therapeutic use; D003371:Cough / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006212:Hallucinations / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D018763:Muscle Fatigue / Q000187:drug effects*; D012307:Risk Factors; D013577:Syndrome
chemical_list: D000996:Antitussive Agents; D001060:Aporphines; C005004:glaucine